Data file (raw data).

BackgroundPatients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer may have poor prognoses and short overall and disease-free survival. Most previous studies focused on assessing the quality of life and health-state utility of the general population of breast cancer patients. The number of studies for HER2-positive breast cancer patients is negligible. This study investigated the health-state utility and its associated factors among Vietnamese patients with HER2-positive breast cancer.MethodsWe conducted face-to-face interviews with 301 HER2-positive breast cancer patients to collect data. Their health-state utility was measured via the EQ-5D-5L instrument. The Mann-Whitney U and Kruskal-Wallis tests were employed to compare the differences in utility scores between two groups and among three groups or more, respectively. Factors associated with patients’ heath-state utility were identified via Tobit regression models.ResultsPain/discomfort (56.1%) and anxiety/depression (39.5%) were the two issues that patients suffered from the most, especially among metastatic breast cancer patients. The severity of distress (depression, anxiety, and stress) in patients was relatively mild. Of 301 patients, their average utility score was 0.86±0.17 (range: 0.03–1.00), and the average EQ-visual analogue scale (VAS) score was 69.12±12.60 (range: 30–100). These figures were 0.79±0.21 and 65.20±13.20 for 102 metastatic breast cancer patients, significantly lower than those of 199 non-metastatic cancer patients (0.89±0.13 and 71.13±11.78) (p.001), respectively. Lower health-state utility scores were significantly associated with older age (p = 0.002), lower education level (p = 0.006), lower monthly income (p = 0.036), metastatic cancer (p = 0.001), lower EQ-VAS score (p.001), and more severe level of distress (p.001).ConclusionsOur findings showed a significant decrement in utility scores among metastatic breast cancer patients. Patients’ health-state utility differed by their demographic characteristics (age, education level, and income) and clinical characteristics (stage of cancer and distress). Their utility scores may support further cost-effectiveness analysis in Vietnam.背景 人表皮生长因子受体2（human epidermal growth factor receptor 2, HER2）阳性乳腺癌患者往往预后较差，总生存期与无病生存期均较短。既往多数研究聚焦于评估乳腺癌普通人群的生活质量与健康效用值（health-state utility），针对HER2阳性乳腺癌患者的相关研究则寥寥无几。本研究旨在探讨越南HER2阳性乳腺癌患者的健康效用值及其影响因素。 方法 本研究对301例HER2阳性乳腺癌患者开展面对面访谈以收集数据，采用EQ-5D-5L量表测量患者的健康效用值。分别采用曼-惠特尼U检验（Mann-Whitney U test）与克鲁斯卡尔-沃利斯检验（Kruskal-Wallis test）比较两组及三组及以上组间效用评分的差异；通过Tobit回归模型识别与患者健康效用值相关的影响因素。 结果 疼痛不适（56.1%）与焦虑/抑郁（39.5%）是患者最常见的两大健康问题，在转移性乳腺癌患者中尤为突出。受试患者的抑郁、焦虑与压力等困扰程度整体偏轻。301例患者的平均健康效用值为0.86±0.17（范围：0.03~1.00），EQ视觉模拟量表（EQ-visual analogue scale, VAS）平均得分为69.12±12.60（范围：30~100）。其中102例转移性乳腺癌患者的对应得分分别为0.79±0.21与65.20±13.20，显著低于199例非转移性乳腺癌患者的0.89±0.13与71.13±11.78（均p<0.001）。较低的健康效用值与高龄（p=0.002）、低受教育水平（p=0.006）、低月收入（p=0.036）、转移性癌症（p=0.001）、低EQ-VAS得分（p<0.001）以及更严重的困扰程度（p<0.001）显著相关。 结论 本研究结果显示转移性乳腺癌患者的效用评分显著降低。患者的健康效用值随人口统计学特征（年龄、受教育水平、收入）与临床特征（癌症分期与困扰程度）存在差异。本研究所得效用评分可为越南地区后续的成本效用分析提供数据支持。